Phase 3b extension study of ligelizumab re-treatment in patients with chronic spontaneous urticaria from earlier trials: 53.5% (72 mg) and 57.5% (120 mg) reached UAS7 ≤6 at week 12, maintained to week 52, with no new safety signals.
RCT
Gimenez-Arnau et al. Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria